ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc (RYTM)

86,40
-1,21
(-1,38%)
Geschlossen 06 Juni 10:00PM
86,40
-0,02
(-0,02%)
Nach Börsenschluss: 1:59AM

Rhythm Pharmaceuticals Inc (RYTM) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
86,40
( -1,38% )
Gebot
82,00
Fragen
120,00
Volumen
446.330
85,44 Tagesbereich 89,325
60,70 52-Wochen-Bereich 122,20
Marktkapitalisierung
Handelsende
87,61
Handelsbeginn
87,74
Letzte Trade
10
@
85
Letzter Handelszeitpunkt
Finanzvolumen
US$ 39.027.255
VWAP
87,4404
Durchschnittliches Volumen (3 Mio.)
US$ 839.385
Ausgegebene Aktien
68.532.607
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-29,62
Gewinn pro Aktie (EPS)
-3,14
Erlöse (LTM)
217,17M
Nettogewinn (LTM)
-202,68M

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin... Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Boston, United States
Gegründet
2026
Rhythm Pharmaceuticals Inc is listed in the Healthcare sector of the NASDAQ with ticker RYTM. The last closing price for Rhythm Pharmaceuticals was US$87,61. Over the last year, Rhythm Pharmaceuticals shares have traded in a share price range of US$ 60,70 to US$ 122,20.

Rhythm Pharmaceuticals currently has 68.532.607 shares in issue. The market capitalisation of Rhythm Pharmaceuticals is US$5,92 billion. Rhythm Pharmaceuticals has a price to earnings ratio (PE ratio) of -29.62.

RYTM Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-6.73-7.2264576398693.1393.582.8951426886.71763104CS
4-9.39-9.8026933917995.7997.4282.8963153089.88889162CS
12-2.44-2.7465105808288.8410074.578918887.3011442CS
26-19.3-18.2592242195105.7122.274.576740795.8227105CS
5222.43564122.260.772442194.44581748CS
15668.55384.03361344517.85122.215.500165010461.72710366CS
26067.81364.76600322818.59122.23.0471608740.62938956CS

RYTM - Frequently Asked Questions (FAQ)

What is the current Rhythm Pharmaceuticals Inc share price?
The current share price of Rhythm Pharmaceuticals Inc is US$ 86,40
How many Rhythm Pharmaceuticals Inc shares are in issue?
Rhythm Pharmaceuticals Inc has 68.532.607 shares in issue
What is the market cap of Rhythm Pharmaceuticals Inc?
The market capitalisation of Rhythm Pharmaceuticals Inc is USD 5,92B
What is the 1 year trading range for Rhythm Pharmaceuticals Inc share price?
Rhythm Pharmaceuticals Inc has traded in the range of US$ 60,70 to US$ 122,20 during the past year
What is the PE ratio of Rhythm Pharmaceuticals Inc?
The price to earnings ratio of Rhythm Pharmaceuticals Inc is -29,62
What is the cash to sales ratio of Rhythm Pharmaceuticals Inc?
The cash to sales ratio of Rhythm Pharmaceuticals Inc is 29,34
What is the registered address of Rhythm Pharmaceuticals Inc?
The registered address for Rhythm Pharmaceuticals Inc is 222 Berkeley Street, Boston, Massachusetts, 02116
What is the Rhythm Pharmaceuticals Inc website address?
The website address for Rhythm Pharmaceuticals Inc is rhythmtx.com
Which industry sector does Rhythm Pharmaceuticals Inc operate in?
Rhythm Pharmaceuticals Inc operates in the Biotechnology & Life Sciences sector

RYTM Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen